UNITED STATES SECURITIES AND EXCHANGE
COMMISSION Washington, D.C. 20549  FORM
10-Q   [X] QUARTERLY REPORT UNDER SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the quarterly period ended March
31, 2008  [
 ] TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the transition period from ___ to
___  Commission file number: 000-30991  SKINOVATION PHARMACEUTICAL INCORPORATED (Exact name of registrant as specified in
its charter)  Nevada
(State or
other jurisdiction of incorporation or organization)
87-0458170
(I.R.S.
Employer  Identification No.)2157 S.
Lincoln Street, Salt Lake City, Utah
(Address of
principal executive offices)
84106
(Zip
Code)  (801) 323-2395 (Registrants telephone number, including
area code)  The registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days.     Yes  [X]   No [  ]  Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company:  Large accelerated filer [
 ]
Non-accelerated filer
  [  ]
Accelerated filed [
 ]
Smaller reporting company
[X]  Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act). Yes [X]   No [  ]  The number of shares outstanding of the registrants
common stock as of May 6, 2008 was 708,000.   1    TABLE OF CONTENTS  PART I  FINANCIAL INFORMATION  Item 1.  Financial
Statements 2 Balance
Sheets 3 Statements
of Operations 4 Statements
of Cash Flows 5 Notes
to the Financial Statements 6 Item 2. Managements Discussion
and Analysis of Financial Condition and Results of Operations 7 Item 3.  Quantitative and
Qualitative Disclosures About Market Risk 7 Item 4.  Controls and
Procedures 8  PART II  OTHER INFORMATION  Item 6.  Exhibits 8 Signatures 9    PART I  FINANCIAL INFORMATION  ITEM 1.  FINANCIAL STATEMENTS  The financial information set forth below with respect to
our statements of operations for the three month periods ended March 31, 2008
and 2007 is unaudited.  This financial information, in the opinion of
management, includes all adjustments consisting of normal recurring entries
necessary for the fair presentation of such data.  The results of
operations for the three month period ended March 31, 2008, are not necessarily
indicative of results to be expected for any subsequent period.    Skinovation Pharmaceutical
Incorporated  (A Development Stage Company)  Financial Statements  March 31, 2008  2    Skinovation Pharmaceutical
Incorporated(A
Development Stage Company)Balance
SheetsMarch 31,

December 31,2008

2007(Unaudited)ASSETSCURRENT
ASSETSCash





$       
        1,837

$       
     2,525Total
Current Assets



1,837

2,525TOTAL
ASSETS




$     
          1,837

$       
     2,525LIABILITIES AND STOCKHOLDER' DEFICITCURRENT
LIABILITIESAccounts
Payable - Related party

$    
         38,726

$  
        38,726Accounts
Payable




27,800

27,100Total
Current Liabilities



66,526

65,826Total
Liabilities




66,526

65,826STOCKHOLDERS'
DEFICITCommon
Stock, $.001 par value; 50,000,000 sharesauthorized;
708,000 shares issued and outstanding

708

708Additional
Paid in Capital



25,148

25,148Deficit
Accumulated During the Development Stage

(90,545)

(89,157)Total
Stockholders' Deficit



(64,689)

(63,301)TOTAL
LIABILITIES AND STOCKHOLDERS' DEFICIT

$     
          1,837

$    
        2,525   The accompanying notes
are an integral part of these financial statements.  3    Skinovation
Pharmaceutical Incorporated(A Development
Stage Company)Statements of
Operations(Unaudited)FromFor the three

For the three

Inception onMonths ended

months ended

January 15,March 31,

March 31,

1988 to2008

2007

March 31, 2008REVENUES






$          
              -

$          
            -

$
           27,937EXPENSESGeneral
& Administrative




1,388

-

155,557TOTAL
EXPENSES





1,388

-

155,557NET
LOSS FROM CONTINUING OPERATIONS
(1,388)

-

(127,620)OTHER
INCOME (EXPENSE)Gain
on disposal of operations



-

-

37,075NET
LOSS BEFORE TAXES




(1,388)

-

(90,545)TAXES






-

-

-NET
LOSS






$
              (1,388)

$         
              -

$
          (90,545)Net
Loss Per Share





$    
              0.00

$
                0.00Weighted
average shares outstanding




708,000

708,000   The accompanying notes
are an integral part of these financial statements.  4    Skinovation
Pharmaceutical Incorporated(A Development
Stage Company)Statements of Cash
Flows(Unaudited)FromInception onJanuary 15,For the three months ended

1988 ThroughMarch 31

March 31,2008

2007

2008Cash
Flows from Operating ActivitiesNet
Loss




$
         (1,388)

$
                -

$       
  (90,545)Adjustments
to reconcile net (loss) to cash provided(used)
by operating activities:Shares
issued for services


-

-

10,433Shares
issued for debt payment

-

-

1,424Loss
on disposal of PP&E


-

-

5,263Changes
in assets and liabilities:Increase
in Accounts Payable and Accrued Liabilities
700

-

66,526Net
Cash Provided (Used) by Operating Activities
(688)

-

(6,899)Cash
Flows from Investing ActivitiesCash
paid for PP&E



-

-

(5,264)Net
Cash Provided (Used) by Investing Activities
-

-

(5,264)Cash
Flows from Financing ActivitiesCash
paid for offering costs


-

-

(7,000)Common
stock issued for cash


-

-

21,000Net
Cash Provided (Used) by Financing Activities
-

-

14,000Increase
(Decrease) in Cash


(688)

-

1,837Cash
and Cash Equivalents at Beginning of Period
2,525

346

-Cash
and Cash Equivalents at End of Period

$
          1,837

$
           346

$        
     1,837Supplemental
Cash Flow Information:Stock
issued for debt payment


$         
          -

$    
            -

$       
      1,424Stock
issued for services


$         
          -

$       
         -

$
          10,433Cash
Paid For:



$         
          -

$    
            -

$  
                   -Interest



$         
          -

$    
            -

$      
               -Income
Taxes    The accompanying notes
are an integral part of these financial statements.   5   Skinovation
Pharmaceutical Incorporated Notes to the Financial Statements March 31, 2008   GENERAL  Skinovation Pharmaceutical Incorporated
(the Company) has elected to omit substantially all footnotes to the financial
statements for the three months ended March 31, 2008 since there have been no
material changes (other than indicated in other footnotes) to the information
previously reported by the Company in their Annual Report filed on the Form 10-K
for the twelve months ended December 31, 2007.  UNAUDITED INFORMATION  The information furnished herein was taken
from the books and records of the Company without audit.  However, such
information reflects all adjustments which are, in the opinion of management,
necessary to properly reflect the results of the interim period presented.
 The information presented is not necessarily indicative of the results
from operations expected for the full fiscal year.   6    In this report references to Skinovation, we,
us, and our refer to Skinovation Pharmaceutical Incorporated.  FORWARD LOOKING STATEMENTS  The Securities and Exchange Commission (SEC) encourages
companies to disclose forward-looking information so that investors can better
understand future prospects and make informed investment decisions.  This
report contains these types of statements.  Words such as may, will,
expect, believe, intend, anticipate, estimate, project, or
continue or comparable terminology used in connection with any discussion of
future operating results or financial performance identify forward-looking
statements.  You are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date of this report.
 All forward-looking statements reflect our present expectation of future
events and are subject to a number of important factors and uncertainties that
could cause actual results to differ materially from those described in the
forward-looking statements.  ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS  Plan of Operation  During the next twelve months our management intends to
actively seek an operating company to acquire or merge with which may provide
operating revenue.  Based on current economic and regulatory conditions,
management believes that it is possible, if not probable, for a company like
ours, without many assets or liabilities, to negotiate a merger or acquisition
with a viable private company.  The opportunity arises principally because
of the high legal and accounting fees and the length of time associated with the
process of going public.  However, should a merger or acquisition prove
unsuccessful, it is possible that we may decide not to pursue further
acquisition activities and management may abandon its activities and our shares
would become worthless.  As of the date of this filing, we have not identified any
assets or business opportunities for acquisition.  Potential investors must
recognize that because we have limited capital available for investigation of
business opportunities and managements limited experience in business analysis,
we may not discover or adequately evaluate adverse facts about any business
opportunity to be acquired.  All risks inherent in new and inexperienced
enterprises are inherent in our plan.  We are a development stage company without revenues from
operations and have had recurring operating losses for the past two fiscal
years.  Our independent auditors have expressed doubt that we can continue
as a going concern unless we obtain financing to continue operations.  At
March 31, 2008, we had $1,837 in cash and total liabilities of $66,526 and we
cannot satisfy our cash requirements for our operations.  We will need to
raise additional capital during the next twelve months to fund our operations
and we will likely rely on equity or debt transactions.  We may issue common stock for cash, to convert debt, or
for services rendered and we anticipate that the common stock will be issued
 pursuant to exemptions to registration provided by federal and state
securities laws.  The purchasers and manner of issuance will be determined
according to our financial needs and the available exemptions to registration.
 We do not currently intend to make a public offering of our stock.
 We also note that if we issue more shares of our common stock, then our
shareholders may experience dilution in the value per share of their common
stock.  During the next twelve months, provided we do not acquire
or merge with an operating business, we do not anticipate that we will conduct
product research and development, nor do we expect to purchase or sell a plant
or equipment, or intend to hire employees.  ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK  Not applicable.   7   ITEM 4.  CONTROLS AND
PROCEDURES  Disclosure Controls and Procedures  We maintain disclosure controls and procedures that are
designed to ensure that information required to be disclosed in our filings
under the Exchange Act is recorded, processed, summarized and reported within
the periods specified in the rules and forms of the SEC.  This information
is accumulated to allow timely decisions regarding required disclosure.
 Our President, who serves as our principal executive officer and principal
financial officer, evaluated the effectiveness of our disclosure controls and
procedures as of the end of the period covered by this report.  Based on
that evaluation, he concluded that our disclosure controls and procedures were
effective.  Managements Report on Internal Control over
Financial Reporting  Our President is responsible to design or supervise a
process to be effected by our board of directors that provides reasonable
assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally
accepted accounting principles.  The policies and procedures include: $ maintenance of records in reasonable
detail to accurately and fairly reflect the transactions and dispositions of
 assets, $ reasonable assurance that
transactions are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting principles, and that
receipts and expenditures are being made only in accordance with authorizations
of management and directors, and $ reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or disposition
of assets that could have a material effect on our financial statements.  Our management determined that there were no changes made
in our internal controls over financial reporting during the first quarter of
2008 that have materially affected or are reasonably likely to materially affect
our internal control over financial reporting.  PART II  OTHER INFORMATION   ITEM 6.  EXHIBITS  Part I Exhibits No. Description 31.1 Principal Executive Officer
Certification 31.2 Principal Financial Officer
Certification 32.1 Section 1350 Certification  Part II Exhibits No. Description 3.1 Articles of Incorporation as amended
 (Incorporated by reference to exhibit 3.1 of the Form 10-KSB, filed March
29, 2002) 3.2 Bylaws of Skinovation (Incorporated
by reference to exhibit 3.3 of the Form 10-SB, filed July 11, 2000)    8   SIGNATURES  Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.  SKINOVATION PHARMACEUTICAL
INCORPORATED



By:    /s/ John W.
Peters
John
W. Peters
President
and Director
Principal
Financial Officer
Date: May 13,
2008   9